{"id":"bl-1020","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Diarrhea"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by blocking the action of vasopressin at the V2 receptor, leading to increased urine production and reduced water reabsorption in the kidneys.","oneSentence":"BL-1020 is a vasopressin V2 receptor antagonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:24:41.028Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Diabetic nephropathy"}]},"trialDetails":[{"nctId":"NCT01363349","phase":"PHASE2, PHASE3","title":"Phase IIb-III Study of BL-1020 Small Molecule for Schizophrenia","status":"TERMINATED","sponsor":"BioLineRx, Ltd.","startDate":"2011-05","conditions":"Schizophrenia, Cognitive Effect on Schizophrenic Patients","enrollment":269},{"nctId":"NCT00722176","phase":"PHASE2","title":"Extension Study To Evaluate The Long-Term Safety, Tolerability, And Efficacy Of Low And High Doses Of Bl-1020","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2008-06","conditions":"Schizophrenia","enrollment":220},{"nctId":"NCT00567710","phase":"PHASE2","title":"A Six-week, Randomized, Double-blind, Placebo-controlled, Parallel Group, Multi-center, Phase II Study","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2008-07","conditions":"Schizophrenia","enrollment":360},{"nctId":"NCT00480246","phase":"PHASE1","title":"A Positron Emission Tomography (PET) Study to Assess the Degree of Dopamine-2 (D2) Receptor Occupancy in the Human Brain After Single Doses of BL-1020 or Perphenazine in Healthy Male Subjects Using [11C]Raclopride as PET Tracer","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2007-05","conditions":"Healthy","enrollment":""},{"nctId":"NCT00480571","phase":"PHASE2","title":"Safety and Tolerability of BL-1020 in Hospitalized Subjects With Chronic Schizophrenia or Schizo-Affective Disorder","status":"COMPLETED","sponsor":"BioLineRx, Ltd.","startDate":"2007-06","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":90}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"BL - 1020","genericName":"BL - 1020","companyName":"BioLineRx, Ltd.","companyId":"biolinerx-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"BL-1020 is a vasopressin V2 receptor antagonist. Used for Diabetic nephropathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}